Actively Recruiting
Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer
Led by Anne Noonan · Updated on 2026-02-11
67
Participants Needed
1
Research Sites
340 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This phase II trial studies how well a biologically optimized infusion schedule of gemcitabine and nab-paclitaxel works in treating patients with pancreatic cancer that has spread to other places in the body (metastatic). Drugs used in chemotherapy, such as gemcitabine and nab-paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Altering the timing of the nab-paclitaxel infusion may improve response in patients with pancreatic cancer.
CONDITIONS
Official Title
Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Confirmed diagnosis of pancreatic adenocarcinoma with metastatic tumors measurable by CT or MRI
- Non-pregnant and non-lactating
- For women of childbearing potential, negative pregnancy test within 72 hours before first treatment
- Agree to use highly effective contraception during treatment and for 3 months after
- No previous chemotherapy or investigational therapy for metastatic pancreatic cancer; prior adjuvant treatment allowed if last chemotherapy was over 6 months ago
- Adequate blood counts and liver function within 14 days before enrollment
- Karnofsky performance status of 60 or higher, or ECOG performance status 0 to 2
- Provided informed consent before study participation
You will not qualify if you...
- Known brain metastases unless treated and stable for at least 3 months
- Active, uncontrolled infections requiring systemic therapy
- Active HIV, hepatitis B, or hepatitis C infections (HIV patients on effective therapy with undetectable viral load within 6 months are eligible)
- Allergy or hypersensitivity to study drugs or their components
- Serious medical risks or psychiatric disorders affecting safety or data integrity
- Unable or unwilling to comply with study procedures
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States, 43210
Actively Recruiting
Research Team
T
The Ohio State University Comprehensive Cancer Center
CONTACT
D
Danielle Trunzo
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here